文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

靶向脂蛋白(a)的小干扰RNA药物Zerlasiran的单次递增剂量与多次给药试验:一项随机临床试验

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

该研究在美国、荷兰、英国和澳大利亚的7个研究中心开展,纳入脂蛋白(a)血清浓度大于150 nmol/L的健康受试者和稳定型动脉粥样硬化性心血管疾病患者,评估Zerlasiran的安全性和耐受性及其对脂蛋白(a)浓度的影响。多次给药组37例患者中36例完成试验,单次给药扩展随访14例中13例完成。无严重不良事件,Zerlasiran耐受性良好,并能以低频给药降低脂蛋白(a)浓度。

要点

  • Zerlasiran耐受性良好,未报告严重不良事件。
  • 单次给药后365天,300 mg组脂蛋白(a)中位变化为-30%,600 mg组为-29%,安慰剂组为14%。
  • 多次给药后脂蛋白(a)最大中位百分比变化:200 mg组-97%、300 mg组-98%、450 mg组-99%,安慰剂组7%。

核心结论

  • Zerlasiran耐受性良好,并能以低频给药降低脂蛋白(a)浓度。

研究设计与样本

  • 单次和多次给药研究,分别纳入健康受试者和稳定型动脉粥样硬化性心血管疾病患者,脂蛋白(a)血清浓度大于150 nmol/L。
  • 研究于2020年11月18日至2023年2月8日在美国、荷兰、英国和澳大利亚的7个研究中心开展,末次随访日期为2023年8月23日。
  • 受试者随机接受单次皮下注射安慰剂(n=8)、Zerlasiran 300 mg(n=6)或600 mg(n=6);或接受2剂安慰剂(n=9)、Zerlasiran 200 mg(n=9,间隔4周)或300 mg(n=9)或450 mg(n=9,间隔8周)。
  • 多次给药组37例患者(平均年龄56岁,标准差10.4;女性15例,占42%)中36例完成试验;单次给药扩展随访的14例受试者中13例完成试验。
  • 主要结局为安全性和耐受性,次要结局包括Zerlasiran血清水平及对脂蛋白(a)血清浓度的影响。

主要发现

  • 无严重不良事件。
  • 多次给药组基线脂蛋白(a)中位浓度为288 nmol/L(四分位距199-352)。
  • 单次给药后365天,脂蛋白(a)浓度中位变化:安慰剂组14%(四分位距13%至15%),Zerlasiran 300 mg组-30%(四分位距-51%至-18%),600 mg组-29%(四分位距-39%至-7%)。
  • 多次给药后脂蛋白(a)浓度最大中位变化:安慰剂组19 nmol/L(四分位距-17至28),200 mg组-258 nmol/L(四分位距-289至-188),300 mg组-310 nmol/L(四分位距-368至-274),450 mg组-242 nmol/L(四分位距-343至-182)。
  • 多次给药后脂蛋白(a)最大中位百分比变化:安慰剂组7%(四分位距-4%至21%),200 mg组-97%(四分位距-98%至-95%),300 mg组-98%(四分位距-99%至-97%),450 mg组-99%(四分位距-99%至-98%);给药后201天分别减弱至0.3%(四分位距-2%至21%)、-60%(四分位距-71%至-40%)、-90%(四分位距-91%至-74%)和-89%(四分位距-91%至-76%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lipoprotein(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis, with no pharmacological treatments approved by regulatory authorities. OBJECTIVES: To assess the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and effects on serum concentrations of lipoprotein(a). DESIGN, SETTING, AND PARTICIPANTS: Single- and multiple-dose study in healthy participants and patients with stable ASCVD, respectively, with lipoprotein(a) serum concentrations greater than 150 nmol/L, conducted at 7 research sites in the US, the Netherlands, UK, and Australia between November 18, 2020, and February 8, 2023, with last follow-up on August 23, 2023. INTERVENTIONS: Participants were randomized to receive (1) a single subcutaneous dose of placebo (n = 8), zerlasiran 300 mg (n = 6) or 600 mg (n = 6); or (2) 2 doses of placebo (n = 9), zerlasiran 200 mg (n = 9) at a 4-week interval or 300 mg (n = 9) or 450 mg (n = 9) at an 8-week interval. MAIN OUTCOMES MEASURES: The primary outcome was safety and tolerability. Secondary outcomes included serum levels of zerlasiran and effects on lipoprotein(a) serum concentrations. RESULTS: Among 37 patients in the multiple-dose group (mean age, 56 [SD, 10.4] years; 15 [42%] women), 36 completed the trial. Among 14 participants with extended follow-up after single doses, 13 completed the trial. There were no serious adverse events. Median baseline lipoprotein(a) concentrations in the multiple-dose group were 288 (IQR, 199-352) nmol/L. Median changes in lipoprotein(a) concentration at 365 days after single doses were 14% (IQR, 13% to 15%) for the placebo group, -30% (IQR, -51% to -18%) for the 300 mg of zerlasiran group, and -29% (IQR, -39% to -7%) for the 600-mg dose group. After 2 doses, maximal median changes in lipoprotein(a) concentration were 19 (IQR, -17 to 28) nmol/L for the placebo group, -258 (IQR, -289 to -188) nmol/L for the 200 mg of zerlasiran group, -310 (IQR, -368 to -274) nmol/L for the 300-mg dose group, and -242 (IQR, -343 to -182) nmol/L for the 450-mg dose group, with maximal median percent change of 7% (IQR, -4% to 21%), -97% (IQR, -98% to -95%), -98% (IQR, -99% to -97%), and -99% (IQR, -99% to -98%), respectively, attenuating to 0.3% (IQR, -2% to 21%), -60% (IQR, -71% to -40%), -90% (IQR, -91% to -74%), and -89% (IQR, -91% to -76%) 201 days after administration. CONCLUSIONS: Zerlasiran was well tolerated and reduced lipoprotein(a) concentrations with infrequent administration. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04606602.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nissen SE, Wolski K, Watts GF, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2024. PMID: 38587822. doi:10.1001/jama.2024.4504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。